Article: Unigene, Glaxo Licensing Deal: Potential $150M For Bone Drug.

West Coast Editor

Although still trading at under a dollar, Unigene Laboratories Inc. saw its stock jump 63 percent on news that GlaxoSmithKline plc signed a licensing deal worth up to $150 million for an oral parathyroid hormone (PTH) analogue still in preclinical studies for osteoporosis.

oThatEs unusual for them,o said Ronald Levy, executive vice president of Fairfield, N.J.-based Unigene. oThey wouldnEt come in this early unless they saw this as a sterling opportunity.o Glaxo, he added, owants to begin the tech transfer today, but we might have to wait a little bit longer.o

UnigeneEs stock (OTCBB:UGNE) closed Monday at 88 cents, up 34 ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!